Revenue Breakdown
Composition ()
No data
Revenue Streams
Fulgent Genetics Inc (FLGT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Institutional, accounting for 58.2% of total sales, equivalent to $48.95M. Other significant revenue streams include Insurance and Patient. Understanding this composition is critical for investors evaluating how FLGT navigates market cycles within the Healthcare Facilities & Services industry.
Profitability & Margins
Evaluating the bottom line, Fulgent Genetics Inc maintains a gross margin of 39.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -18.26%, while the net margin is -8.12%. These profitability ratios, combined with a Return on Equity (ROE) of -3.80%, provide a clear picture of how effectively FLGT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, FLGT competes directly with industry leaders such as PSNL and GDRX. With a market capitalization of $724.59M, it holds a significant position in the sector. When comparing efficiency, FLGT's gross margin of 39.83% stands against PSNL's 13.20% and GDRX's 82.22%. Such benchmarking helps identify whether Fulgent Genetics Inc is trading at a premium or discount relative to its financial performance.
